Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more comprehensive approach to diagnosis, treatment, and research that goes beyond neurologists’ understanding of ...
A Brigham and Women’s Hospital study of 30 people found that, in patients with MS, advanced brain imaging could identify hidden inflammation not picked up on traditional MRIs The new technique could ...
Antonio Scalfari, MD, PhD, of Imperial College London in England, describes smoldering MS, the process they have been using to help better define it, and the importance of the work they are doing.
Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...
Emerging science is shaking up what has been previously known about multiple sclerosis (MS), changing our understanding of the basic biology of the disease. For years, the classical picture of MS has ...
How Long Does It Take to See a Neurologist? On average, older adults waited 34 days for a new visit to a neurologist after a referral, and nearly 20% waited more than 3 months, new Medicare data ...
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation ...
This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS. The top 5 most-read multiple sclerosis ...
News-Medical.Net on MSN
Periodontal bacterial load associated with disease severity in multiple sclerosis
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback